Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

PURPOSE. Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2‐positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Dall, Peter, Koch, Thorsten, Göhler, Thomas, Selbach, Johannes, Ammon, Andreas, Eggert, Jochen, Gazawi, Nidal, Rezek, Daniela, Wischnik, Arthur, Hielscher, Carsten, Keitel, Stella, Cirrincione, Ursula, Hinke, Axel, Feisel‐Schwickardi, Gabriele
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330700/
https://ncbi.nlm.nih.gov/pubmed/28174294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0193
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados